MEI Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 102
- Market Cap
- -
- Website
- http://www.meipharma.com
- Introduction
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.
Clinical Trials
28
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05824559
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Mount Sinai Miami, Miami Beach, Florida, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- MEI Pharma, Inc.
- Registration Number
- NCT05209308
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
- Conditions
- Follicular Lymphoma (FL)Marginal Zone LymphomaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT04745832
- Locations
- 🇺🇸
The Oncology Institute of Hope and Innovation, Riverside, California, United States
🇺🇸Orange Coast Memorial Medical Center, Fountain Valley, California, United States
🇺🇸Long Beach Memorial Medical Center, Long Beach, California, United States
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
- Conditions
- Non Hodgkin LymphomaFollicular Lymphoma (FL)Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT03768505
- Locations
- 🇺🇸
Oncology Institute of Hope and Innovation, Tucson, Arizona, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Tower Hematology Oncology, Beverly Hills, California, United States
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Acute Myeloid Leukemia (AML)Marginal Zone Lymphoma (MZL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Small Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03547115
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- Next
News
Major Kinase Inhibitor Summit to Showcase Next-Generation Cancer Therapeutics Advances
Leading pharmaceutical companies including Pfizer, MEI Pharma, and Onconova Therapeutics will present breakthrough developments in kinase inhibitor research at the upcoming Boston summit in February 2023.